LivaNova Reports Q1 2025 Earnings with Strong Organic Revenue Growth
LivaNova reported Q1 2025 earnings with 10% organic revenue growth, driven by strong performance in the Cardiopulmonary segment and Neuromodulation in Europe and the Rest of the World. Total revenue reached $317 million, with adjusted operating income at $65 million and adjusted diluted EPS at $0.88, up 21% year-over-year. The company raised its full-year revenue growth guidance to 7% to 8%.
Tickers: $LIVN
Topics: cardiopulmonary epilepsy guidance_update organic_growth revenue_growth